Planning and Evaluation supports the scientific and administrative evaluation and strategic planning of all major initiatives at the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC). The leadership of the WFBCCC uses both internal and external committees and boards to obtain substantive advice to inform the decision-making process and continuously develop and modify the plans of the Center. The WFBCCC Director, Boris Pasche, M.D., Ph.D., has strategically enhanced the WFBCCC's leadership as follows: ? The Senior Leadership Committee meets weekly to discuss and evaluate the day-to-day strategic planning initiatives and is comprised of the Director, Deputy Director, Associate Directors, Program Leaders and Co-Leaders, and the Director of Finance. ? The Internal Advisory Board meets monthly to provide the primary decision-making for the WFBCCC and is comprised of the Director, Deputy Director, Associate Directors, Program Leaders, a multi- disciplinary group of leaders chosen for their leadership and advocacy in the WFBCCC, and key administrative staff members. ? The Institutional Executive Advisory Committee, chaired by the Dean of the School of Medicine, is comprised of leaders and representatives of other Centers from Wake Forest Baptist Medical Center, Wake Forest University (undergraduate and graduate school campus), and the joint Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences. In these quarterly meetings, the WFBCCC Director advocates for the Center and promotes interactions on issues pertaining to institutional commitment, recruitment, alignment of strategic priorities, new research collaborations, and opportunities to support Institution-wide research initiatives. ? The External Advisory Board is comprised of external advisors who are directors, senior researchers, and administrative leaders from other NCI-designated Centers and has provided invaluable feedback to the WFBCCC. The Board was expanded in 2014 and 2015 after Dr. Pasche became the WFBCCC Director. The EAB now has 12 members, 3 of whom have served previously, These various advisory group meetings ? in conjunction with membership retreats, Shared Resource quarterly meetings, and ad hoc external advisory meetings ? have helped the WFBCCC develop a new five-year strategic plan, enhance scientific expertise through targeted recruitment, expand Shared Resources to address the changing needs of investigators, form new collaborations among investigators on important topics (e.g. cognition and cancer, genomics, biomedical engineering), and strengthen the overall institutional support and commitment to the WFBCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-46
Application #
10092981
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-02-01
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
46
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Haas, Karen M; Johnson, Kristen L; Phipps, James P et al. (2018) CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens. J Immunol 200:1671-1681
Suo, Xubin; Eldridge, Brittany N; Zhang, Han et al. (2018) P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon Nanotubes. ACS Appl Mater Interfaces 10:33464-33473
Widner, D Brooke; Park, Sun H; Eber, Matthew R et al. (2018) Interactions Between Disseminated Tumor Cells and Bone Marrow Stromal Cells Regulate Tumor Dormancy. Curr Osteoporos Rep 16:596-602
Liu, Liang; Ruiz, Jimmy; O'Neill, Stacey S et al. (2018) Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Mol Cancer 17:81
Sirkisoon, Sherona R; Carpenter, Richard L; Rimkus, Tadas et al. (2018) Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene 37:2502-2514
Goyal, Amrita; Carter, Joi B; Pashtan, Itai et al. (2018) Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study. J Am Acad Dermatol 78:408-410
Su, Weijun; Hong, Lixin; Xu, Xin et al. (2018) miR-30 disrupts senescence and promotes cancer by targeting both p16INK4A and DNA damage pathways. Oncogene 37:5618-5632
Miller Jr, David P; Denizard-Thompson, Nancy; Weaver, Kathryn E et al. (2018) Effect of a Digital Health Intervention on Receipt of Colorectal Cancer Screening in Vulnerable Patients: A Randomized Controlled Trial. Ann Intern Med 168:550-557
Rimkus, Tadas K; Carpenter, Richard L; Sirkisoon, Sherona et al. (2018) Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. Cancer Res 78:2589-2600

Showing the most recent 10 out of 548 publications